T-Cell Lymphoma Clinical Trials 2022

Browse 17 T Cell Lymphoma Medical Studies Across 61 Cities

116 T Cell Lymphoma Clinics

Reviewed by Michael Gill, B. Sc.
Photo of washington 1
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Tagraxofuspfor Lymphoma, B-Cell

Washington, United States
< 65
All Sexes
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Phase 1
Waitlist Available
17 T Cell Lymphoma Clinical Trials Near Me
New York, NY
Washington, United States
Portland, OR
Houston, TX
More Trial Locations
An interactive map to display trial locations for Memorial Sloan Kettering Cancer Center, Children's National Medical Center, Oregon Health & Science University, Texas Children's Hospital/Baylor College of Medicine, and 103 more locations.
Top Hospitals for T Cell Lymphoma Clinical Trials
Location
Active T Cell Lymphoma Clinical Trials
All Time Trials for T Cell Lymphoma
First Recorded T Cell Lymphoma Trial
Trials
Memorial Sloan Kettering Cancer Center, New York, New York
2
23
2005
Oregon Health & Science University, Portland, Oregon
2
5
2015
Dana-Farber Cancer Institute, Boston, Massachusetts
2
16
2005
Memorial Sloan-Kettering Cancer Center, New York, New York
2
15
2001
University of Alabama at Birmingham, Birmingham, Alabama
2
9
2008
Top Treatments for T Cell Lymphoma Clinical Trials
Treatment Name
Active T Cell Lymphoma Clinical Trials
All Time Trials for T Cell Lymphoma
First Recorded T Cell Lymphoma Trial
Trials
Quality-of-Life Assessment
1
5
2016
Top Cities for T Cell Lymphoma Clinical Trials
City
Active T Cell Lymphoma Clinical Trials
Top Active Site for T Cell Lymphoma Clinical Trials
Trial List
New York, New York
8
Memorial Sloan Kettering Cancer Center
Boston, Massachusetts
6
Dana-Farber Cancer Institute
Houston, Texas
5
Texas Children's Hospital/Baylor College of Medicine
Philadelphia, Pennsylvania
5
Thomas Jefferson University
Which phases are most popular for t-cell lymphoma clinical trials?
How many t-cell lymphoma clinical trials are open to youth and / or seniors?
Age Group
Active T Cell Lymphoma Clinical Trials
Trial List
Most Recent T Cell Lymphoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
8/3/2022
Phase 1 & 2
Pediatric T Cell Lymphoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Senior Friendly T Cell Lymphoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
8/3/2022
Phase 1 & 2
Recently Completed Studies with FDA Approved Treatments for T Cell Lymphoma
Treatment
Year
Mechanism of Action
Sponsor
Active T Cell Lymphoma Clinical Trials
rhIL-15
2019
National Cancer Institute (NCI)
0
Anti-CD30-CAR T cells
2017
National Cancer Institute (NCI)
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: September 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.